C12orf52 Inhibitors
Chemical inhibitors of C12orf52 can effectively disrupt its functional activity by targeting various signaling pathways and kinases that are essential for its operation. Wortmannin and LY294002 are both potent inhibitors of PI3K, a pivotal enzyme in the PI3K/AKT signaling pathway, which is known to play a crucial role in the regulation of numerous cellular processes. The inhibition of PI3K by these chemicals can prevent the downstream phosphorylation and activation of AKT, thereby impeding the signaling cascade necessary for C12orf52 to exert its effects. Staurosporine, as a broad-spectrum kinase inhibitor, can indiscriminately inhibit a wide range of kinases within the cellular signaling networks, including those associated with C12orf52, leading to a comprehensive blockade of its functional activity. Rapamycin specifically targets mTOR, another key kinase in cell growth and proliferation pathways, and its inhibition results in the disruption of signaling mechanisms critical to C12orf52's role.
In addition to these, SB203580 and U0126 are selective inhibitors of the MAPK pathway, with SB203580 targeting p38 MAPK and U0126 specifically inhibiting MEK1/2. By preventing the activation of these kinases, both chemicals can impede the MAPK signaling pathway, which is integral to C12orf52 functionality. Similarly, PD98059 focuses on the MEK inhibitor, blocking the activation of ERK, another essential component of the MAPK pathway, which in turn can inhibit the activity of C12orf52. SP600125 is a JNK inhibitor that can inhibit C12orf52 by obstructing the JNK signaling pathway, a potential route through which C12orf52 could operate. PP2, a Src family kinase inhibitor, can halt signaling upstream of C12orf52, while Dasatinib, by targeting Bcr-Abl and Src family kinases, can also suppress the signaling pathways that contribute to the activity of C12orf52. Sorafenib and Sunitinib, both tyrosine kinase inhibitors, can inhibit various kinases that are necessary for the signaling pathways in which C12orf52 is involved, thereby leading to an inhibition of its activity. Each of these chemical inhibitors can impede the functional activity of C12orf52 through interference at different junctures in the signaling networks within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. Since C12orf52 is involved in signaling pathways that require PI3K activity for signal transduction, inhibition of PI3K by Wortmannin would prevent the downstream effects that contribute to the functional activity of C12orf52. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, which would similarly inhibit the phosphorylation and activation of AKT. Given that C12orf52 operates downstream of PI3K/AKT signaling, LY294002 would inhibit the functional activity of C12orf52 by preventing necessary phosphorylation events. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that would inhibit multiple kinases within signaling pathways involving C12orf52. This would result in a wide-ranging inhibition of the functional activity of C12orf52 due to the blockade of its associated kinases. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR, a key component in cell growth and proliferation pathways. Inhibition of mTOR by Rapamycin would disrupt the signaling pathways necessary for C12orf52's activity, resulting in its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, an enzyme in the MAPK pathway. C12orf52's activity is contingent on MAPK signaling; hence, SB203580 inhibits C12orf52 by preventing activation of downstream components that C12orf52 relies on. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK, which is necessary for C12orf52's activity, thus inhibiting the protein's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that prevents MEK from activating ERK in the MAPK pathway. Since C12orf52's activity is dependent on MAPK signaling, PD98059 would inhibit the function of C12orf52 through blockade of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which would inhibit C12orf52 by blocking the JNK signaling pathway, one of the possible pathways that C12orf52 could rely on for its activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Since Src kinases can be upstream regulators in pathways involving C12orf52, PP2 would inhibit the functional activity of C12orf52 by preventing Src kinase signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Bcr-Abl and Src family kinase inhibitor. By inhibiting these kinases, Dasatinib would inhibit the signaling pathways that contribute to the activity of C12orf52, resulting in its functional inhibition. | ||||||